Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R<
Source check: Needs source check. Not independent scientific confirmation.
Finding / tested result: Model screening followed by docking and purchased-compound assays identified a new EGFR inhibitor with cellular activity.
Technology: Random forest classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Random forest classifier is the AI method documented in the editorial source review.
- Limitation / still unknown
- The date refers to the cited version. Earlier public versions and independent replication were not systematically verified.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s13065-024-01279-z · https://doi.org/10.1186/s13065-024-01279-z
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.